The forthcoming discussion of this HST evaluation has been rescheduled. During the clinical expert selection process it was highlighted clinical experts would be unavailable to attend the NICE committee meeting as the Royal College of Ophthalmologists are holding their annual congress in Glasgow on 21 May 2019. NICE recognises the importance of clinical experts contribution to committee discussions. Therefore voretigene neparvovec for treating inherited retinal dystrophies caused by RPE65 gene mutations will now be considered by the HST committee on Thursday 25 July 2019.